Photo by nci from unsplash
vs 10.7%, p = 0.18) GVHD were also comparable as well as 2‐year GVHD free/relapse‐free survival (FB2: 44.4% vs 42.8%, p = 0.38). In multivariate analysis, there was a trend… Click to show full abstract
vs 10.7%, p = 0.18) GVHD were also comparable as well as 2‐year GVHD free/relapse‐free survival (FB2: 44.4% vs 42.8%, p = 0.38). In multivariate analysis, there was a trend for worse outcome using FB3/FB4 regimens (OS: HR 1.46, 95%CI: 0.96‐2.23, p = 0.07; LFS: HR 1.43, 95%CI: 0.99‐2.06, p = 0.05; RI: HR 1.54, 95%CI: 0.95‐2.48, p = 0.07). These results were also confirmed using a propensity score‐matching strategy including 184 FB2 and 98 FB3/4 patients. Conclusion: This large retrospective study showed that reduced toxicity myeloablative fludarabine/busulfan regimens did not improve outcomes of adults allografted for NHL. FB2 conditioning regimen still should be considered as the standard of care conditioning regimen in this setting.
Journal Title: Hematological Oncology
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!